Coherus Oncology

Coherus Oncology is a fully integrated commercial-stage innovative oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a promising pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Our strategy is to expand the use of LOQTORZI in NPC and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our industry partners, driving synergies from proprietary combinations, including first-in-class anticancer agents. If you are interested in joining a highly innovative and exciting company, please visit our careers webpage at http://www.coherus.com/careers/ for a list of career opportunities.

counsyl

Formed in 2018, Myriad Women’s Health is a combination of Counsyl, Inc. and Myriad Preventive Care, a part of Myriad Genetic Laboratories, Inc. Please follow Myriad Genetics for the latest updates.

Prolacta Bioscience

Prolacta Bioscience is a privately-held life sciences company dedicated to Advancing the Science of Human Milk to bring the healing power of breast milk to the most critically ill infants in neonatal care. Prolacta’s human milk-based neonatal nutritional products are changing the standard of care for preemies in hospitals nationwide. Connect with us: www.prolacta.com | Facebook @prolacta | Twitter @prolacta | Instagram @prolacta_bioscience

Sutro Biopharma, Inc.

Sutro Biopharma, Inc., is a clinical-stage company relentlessly focused on the discovery and development of precisely designed cancer therapeutics, transforming what science can do for patients. Sutro’s fit-for-purpose technology, including cell-free XpressCF®, provides the opportunity for broader patient benefit and an improved patient experience. Sutro has multiple clinical stage candidates, including luveltamab tazevibulin, or luvelta, a registrational-stage folate receptor alpha (FolRα)-targeting ADC in clinical studies. A robust pipeline, coupled with high-value collaborations and industry partnerships, validates our continuous product innovation. Sutro is headquartered in South San Francisco. For more information, follow Sutro on social media @Sutrobio, or visit www.sutrobio.com.

Singular Genomics

Singular Genomics is inventing at the forefront of genomics, one of the world’s fastest-growing industries. We are a publicly traded life science technology company that is leveraging novel, next-generation sequencing (NGS) and multi-omics technologies to build products that empower researchers and clinicians. The G4 Sequencing Platform, our first commercially available product, is a powerful, highly versatile benchtop genomic sequencer designed to produce fast and accurate results. In development, the PX system leverages Singular’s proprietary sequencing technology, applying it as an in-situ readout to look at RNA and proteins in single cells and tissue. We are committed to unlocking the potential of our core technologies to reshape the future of genomics. We offer a dynamic, fast-paced, results-oriented environment where employees can make a significant impact in a rapidly expanding company. Innovation, continuous learning, multi-disciplinary collaboration, and diversity of thought are pillars of our culture.